# Phase 2 Multiple Sclerosis trials recruiting: 38 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 38 trials in phase 2 for Multiple Sclerosis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Multiple Sclerosis trials: 38 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/multiple-sclerosis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 38
- Recruiting or not yet: 38
- Read on: November 19, 2026

## Trials

The 25 newest of 38, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 25, 2026 | NCT07840326 | A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS) | Sundance Biosciences, Inc. | Phase 2 | Recruiting | Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS)... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840326) |
| September 18, 2026 | NCT07827716 | A Study to Evaluate the Preliminary Efficacy and Safety of Terfenadine in Patients With Relapsing-Remitting Multiple Sclerosis | Sponsor not shown (see the record) | Phase 2 | Recruiting | Relapsing Remitting Multiple Sclerosis | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827716) |
| August 20, 2026 | NCT07776743 | A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis | Guangzhou Lupeng Pharmaceutical Company LTD. | Phase 2 | Recruiting | Relapsing-remitting Multiple Sclerosis (RRMS) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07776743) |
| August 14, 2026 | NCT07765212 | Evaluating the Use of Oral Indapamide to Reduce Disabiltiy Progression in Progressive Multiple Sclerosis (MS) | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Multiple Sclerosis | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07765212) |
| April 8, 2026 | NCT07517185 | The HIt HArd and hiT Early in Multiple Sclerosis Trial | Uppsala University | Phase 2 | Recruiting | Relapsing-remitting Multiple Sclerosis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07517185) |
| April 3, 2026 | NCT07510607 | Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis | Sponsor not shown (see the record) | Phase 2 | Recruiting | Multiple Sclerosis, RRMS, Relapsing Remitting MS | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07510607) |
| March 31, 2026 | NCT07503873 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative... | TG Therapeutics, Inc. | Phase 2 | Recruiting | Multiple Sclerosis | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07503873) |
| March 31, 2026 | NCT07503340 | A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab... | Hoffmann-La Roche | Phase 2 | Not yet recruiting | Relapsing-remitting Multiple Sclerosis | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07503340) |
| March 27, 2026 | NCT07497399 | Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis | Johns Hopkins University | Phase 2 | Recruiting | Multiple Sclerosis | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07497399) |
| December 30, 2025 | NCT07310914 | Implementation of an Advanced Telerehabilitation Solution for People With Multiple Sclerosis | Danish Multiple Sclerosis Hospitals | Phase 2 | Not yet recruiting | Multiple Sclerosis | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07310914) |
| December 15, 2025 | NCT07282574 | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in... | Hoffmann-La Roche | Phase 2 | Recruiting | Progressive Multiple Sclerosis | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07282574) |
| December 4, 2025 | NCT07263607 | A Multicenter Clinical Trial Evaluating the Efficacy and Safety of Taurine as an Adjunctive Therapy in Multiple Sclerosis | Sichuan Academy of Medical Sciences | Phase 2 | Not yet recruiting | Multiple Sclerosis (MS) Relapsing Remitting | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07263607) |
| October 30, 2025 | NCT07222956 | A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS)... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07222956) |
| June 13, 2025 | NCT07020715 | A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis | University Hospital, Antwerp | Phase 2 | Not yet recruiting | Multiple Sclerosis | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07020715) |
| June 3, 2025 | NCT07002034 | RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | Reunion Neuroscience Inc | Phase 2 | Recruiting | Adjustment Disorder | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07002034) |
| May 7, 2025 | NCT06961383 | Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis | NeuroGenesis Ltd. | Phase 2 | Not yet recruiting | Secondary Progressive Multiple Sclerosis (SPMS) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06961383) |
| May 4, 2025 | NCT06956326 | Illuminating New Paths in the Treatment of Multiple Sclerosis Relapses - Early and Specialized Rehabilitation | Sponsor not shown (see the record) | Phase 2 | Recruiting | Multiple Sclerosis | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06956326) |
| March 30, 2025 | NCT06901687 | Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS) | NYU Langone Health | Phase 2 | Recruiting | Multiple Sclerosis, Depression | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06901687) |
| March 24, 2025 | NCT06890923 | Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis | Tiziana Life Sciences LTD | Phase 2 | Recruiting | Non-Active Secondary Progressive Multiple Sclerosis | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06890923) |
| January 20, 2025 | NCT06782724 | Psilocybin Therapy for Psychological Distress in Palliative Patients | University Medical Center Groningen | Phase 2 | Recruiting | COPD (Chronic Obstructive Pulmonary Disease), ALS (Amyotrophic Lateral Sclerosis), MS (Multiple Sclerosis), Major... | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06782724) |
| January 20, 2025 | NCT06782490 | A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity | Celgene | Phase 2 | Recruiting | Multiple Sclerosis Spasticity | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06782490) |
| December 16, 2024 | NCT06735248 | A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years | ModernaTX, Inc. | Phase 2 | Recruiting | Multiple Sclerosis | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06735248) |
| September 19, 2024 | NCT06599307 | The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis | Cairo University | Phase 2 | Recruiting | Secondary Progressive Multiple Sclerosis (SPMS) | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06599307) |
| September 19, 2024 | NCT06592352 | MODAFIMS: A Trial to Evaluate Predictors of Response to MODAFinil in Patients With Multiple Sclerosis | Clinical Academic Center (2CA-Braga) | Phase 2 | Recruiting | Multiple Sclerosis, Cognitive Impairment | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06592352) |
| June 18, 2024 | NCT06463743 | Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS) | State University of New York at Buffalo | Phase 2 | Recruiting | Multiple Sclerosis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06463743) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 2 |
| Johns Hopkins University | 2 |
| University of California, San Francisco | 1 |
| [TG Therapeutics, Inc.](https://specstream.ai/data/clinical-trials/company/tg-therapeutics-inc) | 1 |
| Uppsala University | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| University of Kansas Medical Center | 1 |
| Danish Multiple Sclerosis Hospitals | 1 |
| Sundance Biosciences, Inc. | 1 |
| NYU Langone Health | 1 |
| [Celgene](https://specstream.ai/data/clinical-trials/company/celgene) | 1 |
| Queen Mary University of London | 1 |
| Sichuan Academy of Medical Sciences | 1 |
| Clinical Academic Center (2CA-Braga) | 1 |
| University Hospital, Antwerp | 1 |
| Guangzhou Lupeng Pharmaceutical Company LTD. | 1 |
| Reunion Neuroscience Inc | 1 |
| State University of New York at Buffalo | 1 |
| [ModernaTX, Inc.](https://specstream.ai/data/clinical-trials/company/modernatx-inc) | 1 |
| University of Calgary | 1 |
| University Medical Center Groningen | 1 |
| Centre hospitalier de l'Université de Montréal (CHUM) | 1 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 1 |
| NeuroGenesis Ltd. | 1 |
| Cairo University | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 17 |
| Poland | 3 |
| France | 3 |
| Australia | 3 |
| Italy | 3 |
| Portugal | 3 |
| United Kingdom | 3 |
| Denmark | 3 |
| Canada | 3 |
| Germany | 2 |
| Spain | 2 |
| Israel | 2 |
| China | 2 |
| Czechia | 2 |
| Bosnia and Herzegovina | 1 |
| Georgia | 1 |
| North Macedonia | 1 |
| Serbia | 1 |
| Ukraine | 1 |
| Sweden | 1 |
| Brazil | 1 |
| Hungary | 1 |
| New Zealand | 1 |
| Turkey (Türkiye) | 1 |
| Ireland | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pediatric endocrinology practices in the United States](https://specstream.ai/data/businesses/pediatric-endocrinology-practices/united-states)
- [Public adjusters in the United States](https://specstream.ai/data/businesses/public-adjusters/united-states)
- [Shutters companies in the United States](https://specstream.ai/data/businesses/shutters-companies/united-states)
- [Textile manufacturers in the United States](https://specstream.ai/data/businesses/textile-manufacturers/united-states)
- [Water softening equipment suppliers in the United States](https://specstream.ai/data/businesses/water-softening-equipment-suppliers/united-states)
- [Arabian restaurants in the United States](https://specstream.ai/data/businesses/arabian-restaurants/united-states)
